Advertisement
AMRN vs CNTB
Which Stock Would AI Choose? Amarin Corporation (AMRN) vs. Connect Biopharma Holdings (CNTB) Stock Comparison
Key Takeaways
- AMRN is a commercial-stage cardiovascular company generating revenue and positive cash flow, while CNTB is a clinical-stage biotech still funding development of an unapproved drug candidate.
- Amarin holds roughly $315 million in cash and investments with no debt, whereas Connect Biopharma recently raised capital to extend its runway into the second half of 2027.
- AMRN's Vascepa faces generic and pricing pressure in the U.S., while CNTB's rademikibart recently missed a Phase 2 asthma endpoint, pressuring its share price.
- CNTB carries a consensus "Strong Buy" analyst rating with price targets well above its recent trading price, reflecting a high-risk, high-upside profile.
- AMRN offers relative stability through an established, revenue-generating product; CNTB offers catalyst-driven volatility tied to clinical and regulatory milestones.
- For more detail on each name, visit AMRN Major News and AMRN Today's Price Move, or CNTB Major News and CNTB Today's Price Move.
- To see how algorithmic systems are positioning across these and other tickers, explore the curated Trending AI Robots.
Introduction
This stock comparison puts two very different healthcare names side by side. AMRN, Amarin Corporation plc, is a commercial-stage pharmaceutical company selling an approved cardiovascular drug, while CNTB, Connect Biopharma Holdings Limited, is a clinical-stage biotech advancing an unapproved antibody for asthma and COPD (chronic obstructive pulmonary disease). Their contrasting risk profiles make this a useful reference point for investors weighing an established, cash-generating business against a speculative, catalyst-driven developer. The comparison is most relevant to traders and investors assessing relative performance, market positioning, and risk tolerance across the biopharmaceutical sector.
AMRN Overview and Recent Performance
Amarin Corporation plc is a pharmaceutical company focused on cardiovascular disease, whose sole marketed product is Vascepa (sold as Vazkepa in Europe), a purified icosapent ethyl therapy used to reduce cardiovascular risk. In recent weeks, the company has continued executing a leaner operating model after completing a global restructuring aimed at roughly $70 million in annual cost savings. Recent quarterly results showed narrower operating losses and a third consecutive quarter of positive operating cash flow, with cash and investments near $315 million and no debt.
Relative performance has been shaped by a dual narrative. Vascepa retains a leading share of the U.S. icosapent ethyl market despite ongoing generic competition, while an exclusive licensing and supply agreement with Recordati has begun scaling Vazkepa across Europe. Still, reported revenue has declined on a year-over-year basis as the company transitions from direct European sales to a partnered model, and U.S. pricing pressure remains a headwind. Sentiment reflects cautious optimism around cash-flow sustainability balanced against single-product concentration risk.
CNTB Overview and Recent Performance
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company headquartered in San Diego, advancing rademikibart, a next-generation antibody targeting IL-4Rα (interleukin-4 receptor alpha) for asthma and COPD. Unlike Amarin, Connect generates negligible product revenue and relies on capital raises to fund development. In recent months, the company completed a roughly $20.2 million private placement, extending its anticipated cash runway into the second half of 2027.
Recent market activity has been volatile. The stock has declined substantially over the year to date, partly reflecting a Phase 2 asthma trial that did not meet its primary endpoint, which one analyst attributed to an atypically low control-arm event rate rather than a lack of drug activity. Positive COPD data, including a reported reduction in treatment failure, has supported the acute-to-chronic development thesis. Despite the drawdown, the analyst consensus remains "Strong Buy," with price targets well above recent trading levels, underscoring the high-risk, high-reward nature of the name.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of algorithmic trading systems from a broader library of hundreds of AI trading bots that monitor thousands of tickers. Each bot operates with its own trading style, strategy, timeframe, performance history, and basket of securities, ranging from short-term momentum models to longer-horizon trend-following approaches. Only the systems considered best-suited to current market conditions earn a place in this featured section, giving traders a filtered view of what the platform's algorithms are prioritizing right now. Exploring the Trending AI Robots can help investors understand how automated strategies are navigating names like AMRN and CNTB alongside the broader market.
Head-to-Head Comparison
The most fundamental contrast is stage of development. AMRN operates a mature, single-product commercial franchise with tangible revenue and improving cash generation, while CNTB is pre-revenue and depends on clinical and regulatory outcomes. Growth drivers differ accordingly: Amarin's trajectory hinges on international market expansion and cost discipline, whereas Connect's hinges on Phase 3 planning and potential FDA (U.S. Food and Drug Administration) alignment for rademikibart.
Risk factors also diverge. Amarin's principal risks are generic erosion, U.S. pricing, and single-asset concentration, but it carries no debt and holds a substantial cash buffer. Connect's risks are binary clinical and financing risks, though its analyst coverage and cash runway provide some cushion. In terms of market sentiment, AMRN's stability-oriented profile contrasts with CNTB's catalyst-driven volatility and wider valuation dispersion among analyst targets.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and relative positioning, Tickeron's AI would likely favor AMRN on a stability and cash-flow basis, given its positive operating cash flow, debt-free balance sheet, and more established market footprint. However, from a momentum-and-catalyst perspective, CNTB may register stronger potential upside signals tied to clinical milestones, though with materially higher volatility. The two names represent fundamentally different risk-reward profiles rather than direct competitors, so any algorithmic preference would depend on the specific strategy and timeframe being applied.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRN is a Hold and CNTB is a Hold.
AMRN in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 28, 2026
AMRN broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 35 of the 38 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In 80 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for AMRN entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Indicator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for AMRN just turned positive on October 22, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in 39 of 54 cases over the following month. The odds of a continued upward trend are 72%.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in 184 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.553) is normal, around the industry mean (-1.421). P/E Ratio (-9.675) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (3.220) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (4.033).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
Momentum Indicator for CNTB turns negative, indicating new downward trend
CNTB saw its Momentum Indicator move below the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 97 similar instances where the indicator turned negative. In 88 of the 97 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CNTB entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CNTB just turned positive on October 07, 2026. Looking at past instances where CNTB's MACD turned positive, the stock continued to rise in 47 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Following a +11.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNTB advanced for three days, in 216 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
CNTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.708) is normal, around the industry mean (3.498). P/E Ratio (-0.612) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (24.272) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CNTB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AMRN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 92 | |
PRICE GROWTH RATING 1..100 | 72 | |
P/E GROWTH RATING 1..100 | 28 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMRN | CNTB | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 79% | 3 days ago 83% |
| Stochastic ODDS (%) | 3 days ago 76% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 89% |
| TrendMonth ODDS (%) | 3 days ago 85% | 3 days ago 89% |
| Advances ODDS (%) | 14 days ago 73% | 14 days ago 89% |
| Declines ODDS (%) | 10 days ago 85% | 3 days ago 87% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMRN’s FA Score shows that 1 FA rating(s) are green while CNTB’s FA Score has 1 green FA rating(s).
- AMRN’s FA Score: 1 green, 4 red.
- CNTB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMRN’s TA Score shows that 4 TA indicator(s) are bullish while CNTB’s TA Score has 5 bullish TA indicator(s).
- AMRN’s TA Score: 4 bullish, 4 bearish.
- CNTB’s TA Score: 5 bullish, 3 bearish.
Price Growth
AMRN (@Pharmaceuticals: Major) experienced а -4.13% price change this week, while CNTB (@Biotechnology) price change was -9.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.85%. For the same industry, the average monthly price growth was -1.19%, and the average quarterly price growth was +4.39%.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
Reported Earning Dates
CNTB is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.85% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (-2.35% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AMRN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMRN has been loosely correlated with CNTB. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRN jumps, then CNTB could also see price increases.
| Ticker / NAME | Correlation To AMRN | 1D Price Change % | ||
|---|---|---|---|---|
| AMRN | 100% | +0.30% | ||
| CNTB - AMRN | 55% Loosely correlated | -0.41% | ||
| HRTX - AMRN | 44% Loosely correlated | +4.64% | ||
| MGNX - AMRN | 44% Loosely correlated | +4.95% | ||
| ALXO - AMRN | 43% Loosely correlated | +0.43% | ||
| ARWR - AMRN | 40% Loosely correlated | +1.22% | ||
More | ||||
CNTB and
Correlation & Price change
A.I.dvisor indicates that over the last year, CNTB has been loosely correlated with AMRN. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CNTB jumps, then AMRN could also see price increases.
| Ticker / NAME | Correlation To CNTB | 1D Price Change % | ||
|---|---|---|---|---|
| CNTB | 100% | -0.41% | ||
| AMRN - CNTB | 55% Loosely correlated | +0.30% | ||
| INKT - CNTB | 31% Poorly correlated | +3.68% | ||
| DNTH - CNTB | 30% Poorly correlated | +3.64% | ||
| ASMB - CNTB | 29% Poorly correlated | +2.10% | ||
| SRRK - CNTB | 29% Poorly correlated | +3.16% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NTSE | 41.82 | 0.87 | +2.13% |
| WisdomTree Emerging Markets Efficient Core Fund (NTSE) | |||
| GSGO | 39.93 | 0.57 | +1.44% |
| Goldman Sachs Growth Opportunities ETF (GSGO) | |||
| QYLD | 17.11 | 0.23 | +1.36% |
| Global X NASDAQ 100 Covered Call ETF (QYLD) | |||
| ENHU | 27.41 | 0.06 | +0.24% |
| iShares Enhanced Large Cap Core Active ETF (ENHU) | |||
| BRES | 24.45 | 0.03 | +0.14% |
| Burney U.S. Equity Select ETF (BRES) | |||